What Researchers Did
Researchers conducted a meta-analysis of nine randomized controlled trials involving 837 patients to evaluate the efficacy and safety of concurrent hyperbaric oxygen therapy (HBOT) with chemoradiotherapy for glioma.
What They Found
Pooled analyses demonstrated that HBOT significantly enhanced objective tumor response rates (odds ratio [OR] = 3.67, 95% CI 2.59-5.18) and improved 3-year overall survival (OR = 0.52, 95% CI 0.33-0.82) when combined with chemoradiotherapy. Additionally, quality of life scores showed marked improvement in HBOT-treated groups (mean difference = 12.33, 95% CI 10.69-13.96).
What This Means for Canadian Patients
For Canadian patients with glioma, these findings suggest that adding hyperbaric oxygen therapy to standard chemoradiotherapy could potentially improve treatment effectiveness and quality of life. This may offer an additional therapeutic option to discuss with their oncology team.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
The study's limitations include potential heterogeneity among the nine included trials and reliance on existing data.